Table of Contents
Vitruvias Therapeutics thyroid recall FDA update: The U.S. Food and Drug Administration (FDA) has raised the risk classification of a recall involving one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg to Class I, the agency’s most serious recall category. The recall concerns tablets that may be superpotent, meaning they could contain more thyroid hormone than intended.
The FDA’s latest action has renewed attention around the Vitruvias thyroid recall, with patients and pharmacies being advised to check product information carefully.
Vitruvias Thyroid Recall: What Happened?
Vitruvias Therapeutics announced the voluntary recall on August 21, 2026, and the FDA published the company’s announcement on August 24. Testing had confirmed the potential for the affected thyroid tablets to be superpotent. The FDA subsequently classified the recall as Class I on September 22, 2026.
An FDA Class I recall is used when there is a reasonable probability that use of or exposure to a recalled product could cause serious adverse health consequences or death. This classification describes the potential risk associated with the recalled product; it does not mean that every person who used it will experience a serious reaction.
Which Vitruvias Thyroid Tablets Are Recalled?
The recall applies to one specific lot of Thyroid Tablets, USP 30 mg. Consumers should compare the information on their medicine bottle with the FDA recall details.
Affected product details:
- Product: Thyroid Tablets, USP 30 mg
- NDC: 69680-166-00
- Lot number: 504950
- Expiration date: September 30, 2026
- Units released: 3,655
- Units sold: 1,955
- Distribution: Nationwide in the United States
According to the FDA, the affected lot was distributed to Vitruvias Therapeutics’ direct accounts between January 31, 2025, and September 30, 2025.
Why Was the Thyroid Medicine Recalled?
The tablets were recalled because testing confirmed their potential to be superpotent. Thyroid Tablets, USP is a natural thyroid preparation derived from porcine thyroid glands and contains levothyroxine and liothyronine. It is used to treat hypothyroidism, commonly known as an underactive thyroid.
Taking more thyroid hormone than intended can cause hyperthyroidism, or an overactive thyroid. The FDA-listed potential symptoms include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heartbeat and abnormal heart rhythms.
Who May Face Greater Risk?
The FDA recall notice identifies elderly patients, pregnant women and infants as groups that may face greater risks from excessive thyroid hormone exposure, particularly with prolonged use.
For older adults, excess thyroid hormone may create particular concerns involving the heart. During pregnancy, overtreatment of hypothyroidism has been associated with complications including premature delivery and low birth weight. In infants, excessive thyroid hormone exposure may affect growth and development.
What Should Patients Do?
Patients who believe they have the recalled Lot 504950 should not stop taking the medicine on their own. The FDA advises patients currently taking the affected product to contact their healthcare provider for guidance and, if appropriate, a replacement prescription.
Anyone experiencing a possible adverse reaction should contact a healthcare professional. Problems related to the product can also be reported through the FDA’s MedWatch safety reporting program.
Vitruvias Therapeutics Update
Vitruvias Therapeutics’ website currently states that the company has ceased operations and that its products are now owned or distributed by H2-Pharma LLC. The website provides updated contact information for reporting suspected adverse events.
The original FDA recall notice stated that Vitruvias Therapeutics had not received reports of adverse events known to be related to the recalled lot at the time of the announcement.
Latest FDA Thyroid Recall News
The Vitruvias Therapeutics thyroid recall is drawing renewed attention because the FDA has now placed the affected lot in its highest recall-risk category. Consumers should carefully check their medicine packaging for NDC 69680-166-00 and Lot 504950 and speak with a healthcare provider if their product matches the recall information.
Patients should rely on the FDA and their healthcare professionals for the latest safety guidance rather than making medication changes without medical advice.
